OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has made significant progress in the clinical development of urcosimod, particularly evident in the promising results from their trials. Specifically, 67% of patients receiving the 0.05% urcosimod formulation reported over a 50% improvement in pain, in stark contrast to 33% in the placebo cohort, indicating a strong therapeutic effect. Additionally, marked reductions in pain scores were observed as early as Week 4, reinforcing the potential effectiveness of urcosimod in treating inflammatory eye diseases and chronic pain.

OKYO Pharma Ltd reported a net loss of $4.7 million for the fiscal year ending March 31, 2025, which translates to a loss of $0.12 per share, indicating ongoing financial challenges for the company. Additionally, the clinical data regarding the 0.05% urcosimod group reveals that all patients had moderate to severe NCP pain scores, suggesting less favorable initial conditions compared to the placebo group, which may impair the treatment's perceived effectiveness. Furthermore, the company faces significant risks including potential clinical trial failures, the possibility of not securing regulatory approval in the U.S., challenges in achieving commercial success, and the risk of dilution, all of which contribute to a negative outlook for its stock performance.